{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:42:58Z","timestamp":1761766978611,"version":"3.41.2"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Insomnia, which is associated with menopausal depression, is a common symptom of menopause. Both symptoms have a common etiology, and can affect each other significantly. Pharmacological interventions, including hypnotics and antidepressants, and non-pharmacological therapies are generally administered in clinical practice for insomnia treatment. As another menopausal disorder, osteoporosis is described as a disease of low bone mineral density (BMD), affecting nearly 200 million women worldwide. Postmenopausal osteoporosis is common among middle-aged women. Since postmenopausal osteoporosis mainly results from low estrogen levels, menopausal hormone therapy (HT) is considered the first-line option for the prevention of osteoporosis during the menopausal period. However, almost no study has evaluated novel treatments for the combined prevention of insomnia, depression, and osteoporosis. Hence, it is necessary to develop new multi-target strategies for the treatment of these disorders to improve the quality of life during this vulnerable period. Melatonin is the major regulator of sleep, and it has been suggested to be safe and effective for bone loss therapy by MT-2 receptor activity. As a result, we hypothesize that agomelatine, an MT-1 and MT-2 receptor agonist and 5-HT<jats:sub>2C<\/jats:sub> receptor antagonist, holds promise in the combined treatment of insomnia, depression, and osteoporosis in middle-aged women during menopause.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.654616","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T04:53:43Z","timestamp":1624942423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model"],"prefix":"10.3389","volume":"12","author":[{"given":"Ahmet","family":"Yardimci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ridvan","family":"Ozdede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haluk","family":"Kelestimur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/NSS.S125807","article-title":"Sleep problems during the menopausal transition: prevalence, impact, and management challenges","volume":"10","author":"Baker","year":"2018","journal-title":"Nat Sci Sleep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.maturitas.2019.02.007","article-title":"Insomnia and depressive symptoms during the menopausal transition: theoretical and therapeutic implications of a self-reinforcing feedback loop","volume":"123","author":"Caruso","year":"2019","journal-title":"Maturitas."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/archinte.166.12.1262","article-title":"Severe hot flashes are associated with chronic insomnia","volume":"166","author":"Ohayon","year":"2006","journal-title":"Arch Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/15402002.2019.1699100","article-title":"Thermal comfort intervention for hot-flash related insomnia symptoms in perimenopausal and postmenopausal-aged women: an exploratory study","volume":"19","author":"Composto","year":"2021","journal-title":"Behav Sleep Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1573400510666140929194848","article-title":"Treatment of insomnia, insomnia symptoms, and obstructive sleep apnea during and after menopause: therapeutic approaches","volume":"11","author":"Tal","year":"2015","journal-title":"Curr Psychiatry Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.maturitas.2019.05.001","article-title":"Insomnia and hot flashes","volume":"126","author":"Bonanni","year":"2019","journal-title":"Maturitas."},{"key":"B7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/13697137.2020.1799973","article-title":"Insomnia and menopause: a narrative review on mechanisms and treatments","volume":"23","author":"Proserpio","year":"2020","journal-title":"Climacteric."},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jad.2016.07.005","article-title":"Patterns of depressive disorders across 13 years and their determinants among midlife women: SWAN mental health study","volume":"206","author":"Bromberger","year":"2016","journal-title":"J Affect Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.maturitas.2014.05.014","article-title":"Menopause and depression: is there a link?","volume":"79","author":"Vivian-Taylor","year":"2014","journal-title":"Maturitas."},{"key":"B10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.maturitas.2015.04.017","article-title":"Sleep disturbances in menopausal women: aetiology and practical aspects","volume":"81","author":"Bruyneel","year":"2015","journal-title":"Maturitas."},{"key":"B11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.sleep.2018.11.019","article-title":"Treating insomnia improves depression, maladaptive thinking, and hyperarousal in postmenopausal women: comparing cognitive-behavioral therapy for insomnia (CBTI), sleep restriction therapy, and sleep hygiene education","volume":"55","author":"Kalmbach","year":"2019","journal-title":"Sleep Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2019.06.008","article-title":"An integrated approach to diagnosing and managing sleep disorders in menopausal women","volume":"128","author":"Caretto","year":"2019","journal-title":"Maturitas."},{"key":"B13","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/GME.0000000000000348","article-title":"Treatment of chronic insomnia disorder in menopause: evaluation of literature","volume":"22","author":"Attarian","year":"2015","journal-title":"Menopause."},{"key":"B14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40675-017-0090-3","article-title":"Insomnia pharmacotherapy: a review of current treatment options for insomnia in menopause","volume":"3","author":"Hachul","year":"2017","journal-title":"Curr Sleep Med Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12020-016-1072-9","article-title":"Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis","volume":"55","author":"Cintron","year":"2017","journal-title":"Endocrine."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/s0022-3956(02)00052-3","article-title":"Place of chronic insomnia in the course of depressive and anxiety disorders","volume":"37","author":"Ohayon","year":"2003","journal-title":"J Psychiatr Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.5665\/sleep.6306","article-title":"DSM-5 insomnia and short sleep: comorbidity landscape and racial disparities","volume":"39","author":"Kalmbach","year":"2016","journal-title":"Sleep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/PSY.0b013e3181d75319","article-title":"Cognitive-emotional hyperarousal as a premorbid characteristic of individuals vulnerable to insomnia","volume":"72","author":"Fern\u00e1ndez-Mendoza","year":"2010","journal-title":"Psychosom Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/ng.3888","article-title":"Genome-wide association analysis of insomnia complaints identifies risk genes and genetic overlap with psychiatric and metabolic traits","volume":"49","author":"Hammerschlag","year":"2017","journal-title":"Nat Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IJWH.S147006","article-title":"Emerging evidence on the link between depressive symptoms and bone loss in postmenopausal women","volume":"10","author":"Mollard","year":"2017","journal-title":"Int J Womens Health."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1089\/jwh.2017.6706","article-title":"Postmenopausal osteoporosis: a clinical review","volume":"27","author":"Watts","year":"2018","journal-title":"J Womens Health."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/17460441.2020.1781087","article-title":"The preclinical discovery and development of agomelatine for the treatment of depression","volume":"15","author":"Konstantakopoulos","year":"2020","journal-title":"Expert Opin Drug Discov."},{"key":"B24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.euroneuro.2012.06.016","article-title":"Synergistic mechanisms involved in the antidepressant effects of agomelatine","volume":"22","author":"Tardito","year":"2012","journal-title":"Eur Neuropsychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.pneurobio.2009.04.007","article-title":"Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine","volume":"88","author":"Pandi-Perumal","year":"2009","journal-title":"Prog Neurobiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.eurpsy.2008.04.002","article-title":"Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system","volume":"23","author":"San","year":"2008","journal-title":"Eur Psychiatry."},{"key":"B27","first-page":"3","article-title":"Agomelatin depresyon tedavisine ne getiriyor?","volume":"51","author":"Cerit","year":"2013","journal-title":"G\u00fcn. G\u00f6zd. Ge\u00e7ir. Yeni Symp."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.4088\/jcp.v68n1112","article-title":"Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine","volume":"68","author":"Lemoine","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1600-079X.2011.00962.x","article-title":"Melatonin and its analogs in insomnia and depression","volume":"52","author":"Cardinali","year":"2012","journal-title":"J Pineal Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"638981","DOI":"10.3389\/fpsyt.2021.638981","article-title":"Melatonin and Depression: a translational perspective from animal models to clinical studies","volume":"12","author":"Tonon","year":"2021","journal-title":"Front Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1176\/ajp.155.8.1119","article-title":"Melatonin for the treatment of sleep disturbances in major depressive disorder","volume":"155","author":"Dolberg","year":"1998","journal-title":"Am J Psychiatry."},{"key":"B32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/YIC.0b013e32832c260b","article-title":"A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood","volume":"25","author":"Serfaty","year":"2010","journal-title":"Int Clin Psychopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jpsychires.2012.08.013","article-title":"An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery","volume":"46","author":"Fava","year":"2012","journal-title":"J Psychiatr Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.euroneuro.2014.08.008","article-title":"The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis","volume":"24","author":"Hansen","year":"2014","journal-title":"Eur Neuropsychopharmacol."},{"key":"B35","doi-asserted-by":"crossref","first-page":"p. 229","DOI":"10.1007\/978-81-322-2803-5_18","article-title":"\u201cAgomelatine, melatonin and depression\u201d","volume-title":"Melatonin, Neuroprotective Agents and Antidepressant Therapy","author":"Norman","year":"2016"},{"key":"B36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3928\/02793695-20071201-04","article-title":"Agomelatine: a novel atypical antidepressant","volume":"45","author":"Howland","year":"2007","journal-title":"J Psychosoc Nurs Ment Health Serv."},{"key":"B37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/11318660-000000000-00000","article-title":"Agomelatine: efficacy at each phase of antidepressant treatment","volume":"23","author":"Kennedy","year":"2009","journal-title":"CNS Drugs."},{"key":"B38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2165\/11534420-000000000-00000","article-title":"Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness","volume":"24","author":"Kennedy","year":"2010","journal-title":"CNS Drugs."},{"key":"B39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1017\/S1461145711001301","article-title":"Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal","volume":"15","author":"Singh","year":"2012","journal-title":"Int J Neuropsychopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0924-977X(06)70009-8","article-title":"Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist","volume":"16","author":"Montgomery Stuart","year":"2006","journal-title":"Eur Neuropsychopharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"g2496","DOI":"10.1136\/bmj.g1888.","article-title":"Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies","volume":"348","author":"Taylor","year":"2014","journal-title":"BMJ."},{"key":"B42","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/14656566.2019.1574747","article-title":"Agomelatine for depression: expanding the horizons?","volume":"20","author":"Norman","year":"2019","journal-title":"Expert Opin Pharmacother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4088\/JCP.12m08250","article-title":"The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study","volume":"74","author":"Heun","year":"2013","journal-title":"J Clin Psychiatry."},{"key":"B44","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s0531-5565(00)00217-5","article-title":"Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study","volume":"36","author":"Bellipanni","year":"2001","journal-title":"Exp Gerontol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1196\/annals.1356.030","article-title":"Effects of melatonin in perimenopausal and menopausal women: our personal experience","volume":"1057","author":"Bellipanni","year":"2005","journal-title":"Ann N Y Acad Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3109\/13697137.2015.1052393","article-title":"Melatonin in aging women","volume":"18","author":"Gursoy","year":"2015","journal-title":"Climacteric."},{"key":"B47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1185\/03007995.2010.537317","article-title":"Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response","volume":"27","author":"Wade","year":"2011","journal-title":"Curr Med Res Opin."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1177\/0269881110379307","article-title":"British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders","volume":"24","author":"Wilson","year":"2010","journal-title":"J Psychopharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"12458","DOI":"10.3390\/ijms140612458","article-title":"The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice","volume":"14","author":"De Berardis","year":"2013","journal-title":"Int J Mol Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/YIC.0b013e328349b117","article-title":"Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients","volume":"26","author":"Quera-Salva","year":"2011","journal-title":"Int Clin Psychopharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/hup.1112","article-title":"Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients","volume":"25","author":"Quera-Salva","year":"2010","journal-title":"Hum Psychopharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e12423","DOI":"10.1111\/jpi.12423","article-title":"Regulation of bone mass through pineal-derived melatonin-MT 2 receptor pathway","volume":"63","author":"Sharan","year":"2017","journal-title":"J Pineal Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e12548","DOI":"10.1111\/jpi.12548","article-title":"et al. Melatonin: another avenue for treating osteoporosis?","volume":"66","author":"Li","year":"2019","journal-title":"J Pineal Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"173577","DOI":"10.1016\/j.ejphar.2020.173577","article-title":"Do peripheral melatonin agonists improve bone fracture healing? The effects of agomelatine and ramelteon on experimental bone fracture","volume":"887","author":"K\u00f6se","year":"2020","journal-title":"Eur J Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/jcp.2010.086595","article-title":"Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis","volume":"64","author":"Jabbar","year":"2011","journal-title":"J Clin Pathol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/bph.14972","article-title":"Melatonin up-regulates bone marrow mesenchymal stem cells osteogenic action but suppresses their mediated osteoclastogenesis via MT2-inactivated NF-\u03baB pathway","volume":"177","author":"Zhou","year":"2020","journal-title":"Br J Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce","year":"2007","journal-title":"Arthritis Res Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5664\/jcsm.26347","article-title":"Menopause related sleep disorders","volume":"1","author":"Eichling","year":"2005","journal-title":"J Clin Sleep Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1111\/jcmm.14170","article-title":"Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment","volume":"23","author":"Fang","year":"2019","journal-title":"J Cell Mol Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.pnpbp.2011.03.013","article-title":"Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics?","volume":"35","author":"Srinivasan","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.afos.2017.05.002","article-title":"Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms","volume":"3","author":"Wadhwa","year":"2017","journal-title":"Osteoporos Sarcopenia."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/j.1368-5031.2005.00681.x","article-title":"Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview","volume":"59","author":"Carrasco","year":"2005","journal-title":"Int J Clin Pract."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0924-9338(14)78345-2","article-title":"EPA-1061\u2013Agomelatine in the treatment of perimenopausal depression-a pilot study","volume":"29","author":"Kr\u00fcger","year":"2014","journal-title":"Eur Psychiatry."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.654616\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T04:53:47Z","timestamp":1624942427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.654616\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":63,"alternative-id":["10.3389\/fpsyt.2021.654616"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.654616","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"article-number":"654616"}}